Leyden Labs
Develop broad-spectrum, self-administered, intranasal antiviral drugs to prevent infection.
Enterprise value
$700m
Company register number
78220521
Recent deals
Authorizing premium user...
Develop broad-spectrum, self-administered, intranasal antiviral drugs to prevent infection.